Purpose: To systematically review available evidence of indirect comparisons from RCTs
and direct comparisons from observational studies regarding the comparative effectiveness …

Background Much direct evidence has proved that the novel oral anticoagulants (NOACs)
are noninferior or superior to warfarin for stroke prevention in patients with nonvalvular atrial …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Background: Direct oral anticoagulants (DOACs) have widely replaced warfarin for stroke
prevention in nonvalvular atrial fibrillation. Our objective was to compare the safety and …

Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …

Abstract Background Direct oral anticoagulants (DOACs) are indicated for the prevention of
stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation. While no …

We performed a meta-analysis of data on the effectiveness and safety of apixaban
compared with other oral anticoagulants (warfarin or rivaroxaban or dabigatran or …

Background and purpose Prospectively collected data comparing the safety and
effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective …

Background The aim of the study was to compare the real-world effectiveness and safety in
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …

Background Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are
lacking in patients with atrial fibrillation (AF). Objective We compared effectiveness and …